COCP · Cocrystal Pharma, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $225.0K | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $1.37M | - | $954.0K | $1.12M | $1.36M | - | $3.24M | $4.31M | $2.95M | - |
| SG&A | $1.21M | - | $1.14M | $986.0K | $981.0K | - | $1.80M | $1.14M | $1.21M | - |
| Total Operating Expenses | $2.58M | - | $2.09M | $2.11M | $2.34M | - | $5.04M | $5.45M | $4.16M | - |
| D&A | $12.0K | - | - | - | $25.0K | - | - | - | $35.0K | - |
| Operating Income | ($2.36M) | - | ($2.09M) | ($2.11M) | ($2.34M) | - | ($5.04M) | ($5.45M) | ($4.16M) | - |
| Interest Expense | ($22.0K) | - | ($22.0K) | ($28.0K) | ($220.0K) | - | ($111.0K) | ($140.0K) | ($220.0K) | - |
| Income Tax | $0 | - | - | - | - | - | - | - | - | - |
| Net Income | ($2.30M) | - | ($2.05M) | ($2.06M) | ($2.30M) | - | ($4.94M) | ($5.34M) | ($3.96M) | - |
| EPS - Basic | ($0.17) | - | ($0.19) | ($0.20) | ($0.23) | - | ($0.49) | ($0.53) | ($0.39) | - |
| EPS - Diluted | ($0.17) | - | ($0.19) | ($0.20) | ($0.23) | - | ($0.49) | ($0.53) | ($0.39) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $4.68M | $7.03M | $7.73M | $4.77M | $6.92M | $9.86M | $13.10M | $18.14M | $21.84M | $26.35M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $1.37M | $890.0K | $745.0K | $856.0K | $808.0K | $1.54M | $859.0K | $1.74M | $1.23M | $1.22M |
| Current Assets | $5.94M | $8.13M | $8.78M | $6.76M | $8.83M | $11.58M | $14.26M | $19.66M | $24.49M | $29.09M |
| Total Assets | $7.43M | $9.71M | $10.45M | $8.51M | $10.66M | $13.46M | $16.23M | $21.57M | $26.55M | $31.26M |
| Current Liabilities | $2.23M | $2.21M | $1.52M | $1.83M | $1.93M | $2.43M | $1.95M | $2.65M | $2.38M | $3.26M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $3.31M | $3.38M | $2.78M | $3.17M | $3.35M | $3.93M | $3.53M | $4.18M | $3.96M | $4.88M |
| Stockholders' Equity | $4.12M | $6.33M | $7.67M | $5.33M | $7.30M | $9.52M | $12.70M | $17.39M | $22.59M | $26.38M |
| Retained Earnings | ($344.55M) | ($342.25M) | ($339.82M) | ($337.77M) | ($335.72M) | ($333.42M) | ($330.15M) | ($325.21M) | ($319.87M) | ($315.91M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($2.34M) | - | - | - | ($2.94M) | - | - | - | ($4.50M) | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - | ($8.0K) | - |
| Financing Cash Flow | - | - | - | - | - | - | - | - | - | - |
| CapEx | - | - | - | - | - | - | - | - | $8.0K | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | ($4.51M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | -1047.1% | - | - | - | - | - | - | - | - | - |
| EBITDA margin | -1041.8% | - | - | - | - | - | - | - | - | - |
| Net margin | -1021.8% | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | 1.14 | - |
| R&D / Revenue | 609.3% | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | 537.8% | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -31.0% | - | -19.6% | -24.2% | -21.6% | - | -30.4% | -24.8% | -14.9% | - |
| Return on equity | -55.9% | - | -26.7% | -38.5% | -31.5% | - | -38.9% | -30.7% | -17.5% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 2.66 | 3.68 | 5.78 | 3.69 | 4.57 | 4.77 | 7.32 | 7.41 | 10.30 | 8.92 |
| Quick ratio | 2.66 | 3.68 | 5.78 | 3.69 | 4.57 | 4.77 | 7.32 | 7.41 | 10.30 | 8.92 |
| Cash ratio | 2.10 | 3.18 | 5.08 | 2.60 | 3.58 | 4.06 | 6.72 | 6.84 | 9.18 | 8.08 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | 107.1x | - | 95.0x | 75.3x | 10.6x | - | 45.4x | 38.9x | 18.9x | - |
| Equity multiplier | 1.80 | 1.53 | 1.36 | 1.59 | 1.46 | 1.41 | 1.28 | 1.24 | 1.18 | 1.18 |
| Liabilities / Assets | 0.45 | 0.35 | 0.27 | 0.37 | 0.31 | 0.29 | 0.22 | 0.19 | 0.15 | 0.16 |
| Efficiency | ||||||||||
| Asset turnover | 0.03 | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 3.4x | - | 1.8x | 2.8x | 2.0x | - | 1.4x | 1.4x | 0.6x | - |
| P / S | 61.9x | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -0.6% | - | 58.6% | 61.3% | 43.7% | - | -13.5% | -25.6% | 18.6% | - |
| Net income growth (YoY) | 0.1% | - | 58.5% | 61.5% | 41.8% | - | -18.6% | -28.3% | 23.8% | - |
| EPS growth (YoY) | 26.1% | - | 61.2% | 62.3% | 41.0% | - | -19.5% | 82.3% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | -42.9% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -43.6% | -33.5% | -39.6% | -69.3% | -67.7% | -63.9% | -58.6% | -49.9% | -34.9% | -33.3% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Cocrystal Pharma against the 5 most active filers in the same SIC group.